News

The company carried out the trial at 12 sites in the US with 450 patients randomized to receive either ITI-007 60 mg or 40 mg or placebo once

GBR 1302 is a HER2xCD3 bi-specific antibody based on Glenmark’s BEAT platform. The drug candidate has the potential to be used in the treatment of an array of

The company carried out the randomized, double-blind, placebo-controlled trial of XP23829 in 33 sites in the US in 200 subjects with moderate-to-severe chronic plaque-type psoriasis. They were randomized

Last month, InSite Vision signed a definite agreement with Canadian drug maker QLT for $0.25 and 0.30 per share. The deal however included a built in clause that

Alector has built a broad platform of new-generation therapeutics, which mobilize the immune system to eliminate multiple disease-causing pathologies. Alector co-founder Asa Abeliovich said: "We have developed a

The Phase 1 study is being performed in asymptomatic "high excreter" (ASHE) patients, who carry the genetic mutation of acute intermittent porphyria (AIP) and have elevated levels of

The product line provides a full assortment of hospital-quality products for consumers categorized as Advanced Wound Care, First Aid, Personal Care, and Home Healthcare which help provide comfort

Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity of Factor Xa inhibitors. Portola is

This registration study enrolled approximately 220 patients at approximately 75 sites in North America, Europe and Asia. ARIAD president of research and development and chief scientific officer Timothy